XTX Topco Ltd Purchases Shares of 29,104 DexCom, Inc. (NASDAQ:DXCM)

XTX Topco Ltd purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 29,104 shares of the medical device company’s stock, valued at approximately $1,951,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom during the 2nd quarter worth $25,000. Sachetta LLC boosted its stake in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after acquiring an additional 171 shares in the last quarter. DT Investment Partners LLC boosted its stake in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares in the last quarter. Riverview Trust Co boosted its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. Finally, ORG Partners LLC boosted its holdings in shares of DexCom by 1,992.0% in the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after buying an additional 498 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

DXCM stock opened at $77.72 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $30.36 billion, a price-to-earnings ratio of 46.54, a P/E/G ratio of 2.48 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a 50 day moving average of $72.55 and a two-hundred day moving average of $86.05.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DXCM shares. Stifel Nicolaus boosted their price target on shares of DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Oppenheimer cut their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Wells Fargo & Company boosted their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Raymond James cut their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.59.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock valued at $399,319 over the last ninety days. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.